Companies
In-Q-Tel
the CIA-affiliated nonprofit venture fund makes direct equity investments in dual-use biotechnology companies spanning gene therapy, lab-grown meat and drug discovery.
- Country
- United States
Nonprofit venture fund
Coverage
| CN | EU | US | |
|---|---|---|---|
| policy-institutions | ✓ | ✓ | ✓ |
Regulatorsfdaepa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Nonprofit venture capital firm created by and affiliated with the CIA and the broader U.S. intelligence and defense community | sociable.co · ui.adsabs.harvard.edu · aol.com |
| Research focus | Deep tech, including biotechnology (gene therapy, lab-grown meat, drug discovery, cellular science), AI and data analytics, cybersecurity, communications, quantum technologies, autonomous technologies, aerospace tech, and advanced materials/semiconductors | sociable.co · iqt.org |
| Facility | IQT Labs | iqt.org |
| Grant | Receives approximately $100 million annually in U.S. taxpayer funding through contracts with the CIA and other government agencies | aol.com · marketplace.org |
| Principal staff | Steve Bowsher (President and CEO), Yan Zheng (Chief of Staff), A.J. Bertone (Managing Partner) | aol.com |
| Headcount | Approximately 100–250 employees | aol.com |
Independent sources: aol.com · iqt.org · marketplace.org · sociable.co · ui.adsabs.harvard.edu
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Defense bioeconomy | policy-institutions | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.